Second cohort enrolled in PD trial

In March 2018, the company announced it had completed dosing of the second cohort of four patients in its Phase I trial of ISC-hpNSC in PD, who are being treated with the 50m cell dose. As a reminder, patients on the study are being treated in three cohorts with 30m, 50m and 70m stem cells, delivered via intracranial injection. Interim data from the first cohort, who were treated at the 30m cell dose, are encouraging. The company expects to start a Phase II PD trial later in 2018.”

Read more:

About is a global financial portal and internet brand composed of 28 editions in 21 languages and mobile apps for Android and iOS that provide news, analysis, streaming quotes and charts, technical data and financial tools about the global financial markets. Each edition covers a broad variety of local and global financial vehicles including Stocks, Bonds, Commodities, Currencies, Interest Rates, Futures and Options. Founded in 2007, has a growing readership worldwide and is now a leading global financial portal committed to constantly launching innovative features and sections to ensure an optimal one-stop source for its readers.